Cargando…

Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD),()()

Detalles Bibliográficos
Autores principales:	Raffi, Jodie, Suresh, Raagini, Berger, Timothy, Fishman, Harvey, Murase, Jenny E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938892/ https://www.ncbi.nlm.nih.gov/pubmed/31909162 http://dx.doi.org/10.1016/j.ijwd.2019.08.007

Ejemplares similares

Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)(,,)()
por: Raffi, Jodie, et al.
Publicado: (2019)

The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy
por: Suresh, Raagini, et al.
Publicado: (2018)

Treatment of moist desquamation for patients undergoing radiotherapy()()
por: Suresh, Raagini, et al.
Publicado: (2019)

Diagnostic testing in gestational bullous pemphigoid: Has enzyme-linked immunosorbent assay replaced direct immunofluorescence as the new gold standard?
por: Abel, Mary Kathryn, et al.
Publicado: (2019)

Clinical recognition and management of alopecia in women of color,()
por: Raffi, Jodie, et al.
Publicado: (2019)

The challenge of diagnosing scabies in the elderly: A case and a novel therapeutic approach
por: Braun, Mitchell, et al.
Publicado: (2020)

Idiopathic pure sudomotor failure: A review and two cases
por: Young, Albert T., et al.
Publicado: (2020)

Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
por: Popiela, Magdalena Z., et al.
Publicado: (2021)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Dupilumab-associated cicatrizing ocular disease
por: Reddy, Amit K., et al.
Publicado: (2022)

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022)

Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting
por: Foley, Peter, et al.
Publicado: (2022)

Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
por: Park, Sunny, et al.
Publicado: (2021)

The use of dupilumab for the treatment of recalcitrant brachioradial pruritus
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Allergic contact dermatitis masquerading as atopic dermatitis
por: Semaan, Sarah, et al.
Publicado: (2020)

Review of Scabies in the Elderly
por: Raffi, Jodi, et al.
Publicado: (2019)

Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series
por: Hébert, Mélanie, et al.
Publicado: (2022)

Cutaneous endometriosis
por: Raffi, Liza, et al.
Publicado: (2019)

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
por: Zirwas, Matthew J., et al.
Publicado: (2018)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

Recalcitrant anal and genital pruritus treated with dupilumab()()()()
por: Yang, E.J., et al.
Publicado: (2018)

Work–life balance among female dermatologists()
por: Raffi, Jodie, et al.
Publicado: (2019)

A clinician's guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults()()()
por: Semaan, Sarah, et al.
Publicado: (2021)

Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study
por: Barbieri, John S., et al.
Publicado: (2021)

Dupilumab for the treatment of severe photodermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab–Associated Conjunctivitis in Patients with Atopic Dermatitis
por: Patra, VijayKumar, et al.
Publicado: (2023)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients
por: Tauqeer, Zujaja, et al.
Publicado: (2022)

Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report
por: Adachi, Rumi, et al.
Publicado: (2022)

Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis
por: Jia, Qian-Nan, et al.
Publicado: (2022)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Clinical Management of Nonsteroidal Anti-inflammatory Drug Hypersensitivity
por: Sánchez-Borges, Mario
Publicado: (2008)

Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity
por: Yeung, Wan Yin Winnie, et al.
Publicado: (2020)

Nonsteroidal Anti-Inflammatory Drugs and Risk of Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2011)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy
por: Huang, Wei, et al.
Publicado: (2023)

Dupilumab-associated blepharoconjunctivitis
por: Paulose, Sefy A., et al.
Publicado: (2019)

Dupilumab for atopic dermatitis
Publicado: (2019)

Ophiasis treated with dupilumab
por: Abercrombie, McKenna, et al.
Publicado: (2021)

Dupilumab-Induced Pancreatitis
por: Jasti, Vivek V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_il2mo0krern7uu8qcoaag7hm87